|
1
|
Ranganathan V, Gracey E, Brown MA, Inman
RD and Haroon N: Pathogenesis of ankylosing spondylitis - recent
advances and future directions. Nat Rev Rheumatol. 13:359–367.
2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Barbulescu AL, Ciurea PL, Mitran C,
Chisalau BA, Parvanescu CD, Firulescu SC, Balasoiu M, Boldeanu MV,
Popoviciu H and Vreju FA: High frequency ultrasonography of the
hand versus anti-RA33 evaluation in early rheumatoid arthritis - a
pilot study. Med Ultrason. 19:166–171. 2017.PubMed/NCBI View
Article : Google Scholar
|
|
3
|
Bărbulescu AL, Sandu RE, Vreju AF, Ciurea
PL, Criveanu C, Firulescu SC, Chisălău AB, Pârvănescu CD, Ciobanu
DA, Radu M, et al: Neuroinflammation in systemic lupus
erythematosus - a review. Rom J Morphol Embryol. 60:781–786.
2019.PubMed/NCBI
|
|
4
|
Sieper J and Poddubnyy D: Pathogenesis of
spondylarthritis: Relevance for treatment. Z Rheumatol. 79:5–12.
2020.PubMed/NCBI View Article : Google Scholar : (In German).
|
|
5
|
Yin J, Sternes PR, Wang M, Song J,
Morrison M, Li T, Zhou L, Wu X, He F, Zhu J, et al: Shotgun
metagenomics reveals an enrichment of potentially cross-reactive
bacterial epitopes in ankylosing spondylitis patients, as well as
the effects of TNFi therapy upon microbiome composition. Ann Rheum
Dis. 79:132–140. 2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Gravallese EM and Schett G: Effects of the
IL-23-IL-17 pathway on bone in spondyloarthritis. Nat Rev
Rheumatol. 14:631–640. 2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Pedersen SJ and Maksymowych WP: The
pathogenesis of ankylosing spondylitis: An update. Curr Rheumatol
Rep. 21(58)2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
van Gaalen FA, Verduijn W, Roelen DL,
Böhringer S, Huizinga TW, van der Heijde DM and Toes RE: Epistasis
between two HLA antigens defines a subset of individuals at a very
high risk for ankylosing spondylitis. Ann Rheum Dis. 72:974–978.
2013.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Reveille JD, Zhou X, Lee M, Weisman MH, Yi
L, Gensler LS, Zou H, Ward MM, Ishimori ML, Learch TJ, et al: HLA
class I and II alleles in susceptibility to ankylosing spondylitis.
Ann Rheum Dis. 78:66–73. 2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Burton PR, Clayton DG, Cardon LR, Craddock
N, Deloukas P, Duncanson A, Kwiatkowski DP, McCarthy MI, Ouwehand
WH, Samani NJ, et al: Breast Cancer Susceptibility Collaboration
(UK): Association scan of 14,500 nonsynonymous SNPs in four
diseases identifies autoimmunity variants. Nat Genet. 39:1329–1337.
2007.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Evans DM, Spencer CC, Pointon JJ, Su Z,
Harvey D, Kochan G, Oppermann U, Dilthey A, Pirinen M, Stone MA, et
al: Spondyloarthritis Research Consortium of Canada (SPARCC);
Australo-Anglo-American Spondyloarthritis Consortium (TASC);
Wellcome Trust Case Control Consortium 2 (WTCCC2): Interaction
between ERAP1 and HLA-B27 in ankylosing spondylitis implicates
peptide handling in the mechanism for HLA-B27 in disease
susceptibility. Nat Genet. 43:761–767. 2011.PubMed/NCBI View
Article : Google Scholar
|
|
12
|
Cauli A, Piga M, Floris A and Mathieu A:
Current perspective on the role of the
interleukin-23/interleukin-17 axis in inflammation and disease
(chronic arthritis and psoriasis). Immunotargets Ther. 4:185–190.
2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Ruiz de Morales JMG, Puig L, Daudén E,
Cañete JD, Pablos JL, Martín AO, Juanatey CG, Adán A, Montalbán X,
Borruel N, et al: Critical role of interleukin (IL)-17 in
inflammatory and immune disorders: An updated review of the
evidence focusing in controversies. Autoimmun Rev.
19(102429)2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Wendling D, Cedoz JP, Racadot E and
Dumoulin G: Serum IL-17, BMP-7, and bone turnover markers in
patients with ankylosing spondylitis. Joint Bone Spine. 74:304–305.
2007.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Mei Y, Pan F, Gao J, Ge R, Duan Z, Zeng Z,
Liao F, Xia G, Wang S, Xu S, et al: Increased serum IL-17 and IL-23
in the patient with ankylosing spondylitis. Clin Rheumatol.
30:269–273. 2011.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Lau MC, Keith P, Costello ME, Bradbury LA,
Hollis KA, Thomas R, Thomas GP, Brown MA and Kenna TJ: Genetic
association of ankylosing spondylitis with TBX21 influences T-bet
and pro-inflammatory cytokine expression in humans and SKG mice as
a model of spondyloarthritis. Ann Rheum Dis. 76:261–269.
2017.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Jethwa H and Bowness P: The interleukin
(IL)-23/IL-17 axis in ankylosing spondylitis: New advances and
potentials for treatment. Clin Exp Immunol. 183:30–36.
2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Cheung PP: Anti-IL17A in axial
spondyloarthritis-where are we at? Front Med (Lausanne).
4(1)2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Dubash S, Bridgewood C, McGonagle D and
Marzo-Ortega H: The advent of IL-17A blockade in ankylosing
spondylitis: Secukinumab, ixekizumab and beyond. Expert Rev Clin
Immunol. 15:123–134. 2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
van der Heijde D, Cheng-Chung Wei J,
Dougados M, Mease P, Deodhar A, Maksymowych WP, van den Bosch F,
Sieper J, Tomita T, Landewé R, et al: COAST-V study group.
Ixekizumab, an interleukin-17A antagonist in the treatment of
ankylosing spondylitis or radiographic axial spondyloarthritis in
patients previously untreated with biological disease-modifying
anti-rheumatic drugs (COAST-V): 16 week results of a phase 3
randomised, double-blind, active-controlled and placebo-controlled
trial. Lancet. 392:2441–2451. 2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Mease PJ, Smolen JS, Behrens F, Nash P,
Liu Leage S, Li L, Tahir H, Gooderham M, Krishnan E, Liu-Seifert H,
et al: SPIRIT H2H study group: A head-to-head comparison of the
efficacy and safety of ixekizumab and adalimumab in
biological-naïve patients with active psoriatic arthritis: 24-week
results of a randomised, open-label, blinded-assessor trial. Ann
Rheum Dis. 79:123–131. 2020.
|
|
22
|
Deodhar A, Gensler LS, Sieper J, Clark M,
Calderon C, Wang Y, Zhou Y, Leu JH, Campbell K, Sweet K, et al:
Three multicenter, randomized, double-blind, placebo-controlled
studies evaluating the efficacy and safety of ustekinumab in axial
spondyloarthritis. Arthritis Rheumatol. 71:258–270. 2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Deveci H, Turk AC, Ozmen ZC, Demir AK and
Say Coskun SU: Biological and genetic evaluation of IL-23/IL-17
pathway in ankylosing spondylitis patients. Cent Eur J Immunol.
44:433–439. 2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Tan ZY, Bealgey KW, Fang Y, Gong YM and
Bao S: Interleukin-23: Immunological roles and clinical
implications. Int J Biochem Cell Biol. 41:733–735. 2009.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Benham H, Rehaume LM, Hasnain SZ, Velasco
J, Baillet AC, Ruutu M, Kikly K, Wang R, Tseng HW, Thomas GP, et
al: Interleukin-23 mediates the intestinal response to microbial
β-1,3-glucan and the development of spondyloarthritis pathology in
SKG mice. Arthritis Rheumatol. 66:1755–1767. 2014.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Bettelli E, Carrier Y, Gao W, Korn T,
Strom TB, Oukka M, Weiner HL and Kuchroo VK: Reciprocal
developmental pathways for the generation of pathogenic effector
TH17 and regulatory T cells. Nature. 441:235–238. 2006.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Lee Y, Awasthi A, Yosef N, Quintana FJ,
Xiao S, Peters A, Wu C, Kleinewietfeld M, Kunder S, Hafler DA, et
al: Induction and molecular signature of pathogenic TH17 cells. Nat
Immunol. 13:991–999. 2012.PubMed/NCBI View
Article : Google Scholar
|
|
28
|
Jansen DT, Hameetman M, van Bergen J,
Huizinga TW, van der Heijde D, Toes RE and van Gaalen FA:
IL-17-producing CD4+ T cells are increased in early,
active axial spondyloarthritis including patients without imaging
abnormalities. Rheumatology (Oxford). 54:728–735. 2015.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Kenna TJ, Davidson SI, Duan R, Bradbury
LA, McFarlane J, Smith M, Weedon H, Street S, Thomas R, Thomas GP,
et al: Enrichment of circulating interleukin-17-secreting
interleukin-23 receptor-positive γ/δ T cells in patients with
active ankylosing spondylitis. Arthritis Rheum. 64:1420–1429.
2012.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Venken K, Jacques P, Mortier C, Labadia
ME, Decruy T, Coudenys J, Hoyt K, Wayne AL, Hughes R, Turner M, et
al: RORγt inhibition selectively targets IL-17 producing iNKT and
γδ-T cells enriched in Spondyloarthritis patients. Nat Commun.
10(9)2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Siloşi CA, Siloşi I, Pădureanu V, Bogdan
M, Mogoantă SŞ, Ciurea ME, Cojocaru M, Boldeanu L, Avrămescu CS,
Boldeanu MV, et al: Sepsis and identification of reliable
biomarkers for postoperative period prognosis. Rom J Morphol
Embryol. 59:77–91. 2018.PubMed/NCBI
|
|
32
|
Baeten D, Østergaard M, Wei JC, Sieper J,
Järvinen P, Tam LS, Salvarani C, Kim TH, Solinger A, Datsenko Y, et
al: Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis:
Results of a randomised, double-blind, placebo-controlled,
proof-of-concept, dose-finding phase 2 study. Ann Rheum Dis.
77:1295–1302. 2018.PubMed/NCBI View Article : Google Scholar
|
|
33
|
McInnes IB, Kavanaugh A, Gottlieb AB, Puig
L, Rahman P, Ritchlin C, Brodmerkel C, Li S, Wang Y, Mendelsohn AM,
et al: PSUMMIT 1 Study Group: Efficacy and safety of ustekinumab in
patients with active psoriatic arthritis: 1 year results of the
phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1
trial. Lancet. 382:780–789. 2013.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Araujo EG, Englbrecht M, Hoepken S, Finzel
S, Kampylafka E, Kleyer A, Bayat S, Schoenau V, Hueber A, Rech J,
et al: Effects of ustekinumab versus tumor necrosis factor
inhibition on enthesitis: Results from the enthesial clearance in
psoriatic arthritis (ECLIPSA) study. Semin Arthritis Rheum.
48:632–637. 2019.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Albu CV, Padureanu V, Boldeanu MV, Bumbea
AM, Enescu AS, Albulescu DM, Silosi CA and Enescu A: Vascular
neurocognitive disorders and the vascular risk factors. J Mind Med
Sci. 5:7–15. 2018.
|
|
36
|
Yago T, Nanke Y, Kawamoto M, Furuya T,
Kobashigawa T, Kamatani N and Kotake S: IL-23 induces human
osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody
attenuates collagen-induced arthritis in rats. Arthritis Res Ther.
9(R96)2007.PubMed/NCBI View
Article : Google Scholar
|
|
37
|
Ju JH, Cho ML, Moon YM, Oh HJ, Park JS,
Jhun JY, Min SY, Cho YG, Park KS, Yoon CH, et al: IL-23 induces
receptor activator of NF-kappaB ligand expression on
CD4+ T cells and promotes osteoclastogenesis in an
autoimmune arthritis model. J Immunol. 181:1507–1518.
2008.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Li X, Kim KW, Cho ML, Ju JH, Kang CM, Oh
HJ, Min JK, Lee SH, Park SH and Kim HY: IL-23 induces receptor
activator of NF-kappaB ligand expression in fibroblast-like
synoviocytes via STAT3 and NF-kappaB signal pathways. Immunol Lett.
127:100–107. 2010.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Chen L, Wei XQ, Evans B, Jiang W and
Aeschlimann D: IL-23 promotes osteoclast formation by up-regulation
of receptor activator of NF-kappaB (RANK) expression in myeloid
precursor cells. Eur J Immunol. 38:2845–2854. 2008.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Caruntu C, Boda D, Dumitrascu G,
Constantin C and Neagu M: Proteomics focusing on immune markers in
psoriatic arthritis. Biomarkers Med. 9:513–528. 2015.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Boda D, Negrei C, Nicolescu F and Badalau
C: Assessment of some oxidative stress parameters in methotrexate
treated psoriasis patients. Farmacia. 62:704–710. 2014.
|
|
42
|
Negrei C, Arsene AL, Toderescu CD, Boda D
and Ilie M: Acitretin treatment may influence the cell membrane
fluidity. Farmacia. 60:767–772. 2012.
|
|
43
|
Kamiya S, Nakamura C, Fukawa T, Ono K,
Ohwaki T, Yoshimoto T and Wada S: Effects of IL-23 and IL-27 on
osteoblasts and osteoclasts: Inhibitory effects on osteoclast
differentiation. J Bone Miner Metab. 25:277–285. 2007.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Zhang JR, Pang DD, Tong Q, Liu X, Su DF
and Dai SM: Different modulatory effects of IL-17, IL-22, and IL-23
on osteoblast differentiation. Mediators Inflamm.
2017(5950395)2017.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Siloşi I, Boldeanu MV, Cojocaru M,
Biciuşcă V, Pădureanu V, Bogdan M, Badea RG, Avramescu C, Petrescu
IO, Petrescu F, et al: The relationship of cytokines IL-13 and
IL-17 with wutoantibodies profile in early rheumatoid arthritis. J
Immunol Res. 2016(3109135)2016.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Siloşi I, Boldeanu L, Biciuşcă V, Bogdan
M, Avramescu C, Taisescu C, Padureanu V, Boldeanu MV, Dricu A and
Siloşi CA: Serum biomarkers for discrimination between hepatitis
C-related arthropathy and early rheumatoid arthritis. Int J Mol
Sci. 18(E1304)2017.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Huang H, Kim HJ, Chang EJ, Lee ZH, Hwang
SJ, Kim HM, Lee Y and Kim HH: IL-17 stimulates the proliferation
and differentiation of human mesenchymal stem cells: Implications
for bone remodeling. Cell Death Differ. 16:1332–1343.
2009.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Osta B, Lavocat F, Eljaafari A and Miossec
P: Effects of interleukin-17A on osteogenic differentiation of
isolated human mesenchymal stem cells. Front Immunol.
5(425)2014.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Silosi I, Cojocaru M, Foia L, Boldeanu MV,
Petrescu F, Surlin P and Biciusca V: Significance of circulating
and crevicular matrix metalloproteinase-9 in rheumatoid
arthritis-chronic periodontitis association. J Immunol Res.
2015(218060)2015.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Shaw AT, Maeda Y and Gravallese EM: IL-17A
deficiency promotes periosteal bone formation in a model of
inflammatory arthritis. Arthritis Res Ther. 18:104–113.
2016.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Kim YG, Park JW, Lee JM, Suh JY, Lee JK,
Chang BS, Um HS, Kim JY and Lee Y: IL-17 inhibits osteoblast
differentiation and bone regeneration in rat. Arch Oral Biol.
59:897–905. 2014.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Ono T, Okamoto K, Nakashima T, Nitta T,
Hori S, Iwakura Y and Takayanagi H: IL-17-producing γδ T cells
enhance bone regeneration. Nat Commun. 7(10928)2016.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Nam D, Mau E, Wang Y, Wright D, Silkstone
D, Whetstone H, Whyne C and Alman B: T-lymphocytes enable
osteoblast maturation via IL-17F during the early phase of fracture
repair. PLoS One. 7(e40044)2012.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Croes M, Öner FC, van Neerven D, Sabir E,
Kruyt MC, Blokhuis TJ, Dhert WJA and Alblas J: Proinflammatory T
cells and IL-17 stimulate osteoblast differentiation. Bone.
84:262–270. 2016.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Li JY, Yu M, Tyagi AM, Vaccaro C, Hsu E,
Adams J, Bellido T, Weitzmann MN and Pacifici R: IL-17 receptor
signaling in osteoblasts/osteocytes mediates PTH-induced bone loss
and enhances osteocytic RANKL production. J Bone Miner Res.
34:349–360. 2019.PubMed/NCBI View Article : Google Scholar
|
